Substituted purine derivatives as inhibitors of cell adhesion

A compound selected from the group consisting of a compound of the formula

• wherein B is (C1-C18)-alkyl, (C3-C14)-cycloalkyl, (C3—C14)-cycloalkyl-(C1-C8)-alkyl-, (C6-C14)-aryl, (C6-C14)-aryl-(C1-C8)-alkyl-, (C6-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C8)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxy-carbonyl-, (C1-C6)-alkoxy, (C1-C6)-alkoxy-(C1-C6)-alkyl-, (C1-C6)-alkoxycarbonyl-, (C1-C6)-alkoxy-(C1-C6)-alkoxy-, (C5-C14)-aryl-(C1-C8)-alkylcarbonyl-, (C1-C6)-alkanoylamino-, (C1-C6)-alkylsulfonylamino-, (C5-C14)-arylsulfonylamino-, (C1-C6)-alkylamino-, di-((C1-C6)-alkyl)-amino-, (C1-C6)-alkylsulfonyl-, aminosulfonyl-, (C5-C14)-arylsulfonyl-, (C5-C14)-aryl-(C1-C8)-alkylsulfonyl-, (C6-C14)-aryl and (C5-C14)-heteroaryl, where all residues B are independent of one another,
• D is selected from the group consisting of —C(O)—N(R6)—, —NR6—C—(O)—, —NR6—C(O)—N(R6)—, —NR6—C(S)—N(R6)—, —C(S)—N(R6)— or —C(R6)═N—N(R6)—, where the divalent Ds are bonded to E via the free bond on their right side;
• E is selected from the group consisting of
• R6—C(═NR6)—NR6— and R6R6′N—C(═NR6)—;
• G is selected from the group consisting of N, CH and C((C1-C4)-alkyl);
• X is selected from the group consisting of hydrogen, —NR6R6′, fluorine, chlorine, bromine, —OR6, —SR6, hydroxy-(C1-C6)-alkyl-NH—, (hydroxy-(C1-C6)-alkyl)2N—, amino-(C1-C6)-alkyl-NH—, (amino-(C1-C6)-alkyl)2N—, hydroxy-(C1-C6)-alkyl-S— and —NH—C(O)—R6;
• Y is selected from the group consisting of R6, fluorine, chlorine, bromine, cyano, —NR6—R6′, —OR6, —SR6 and hydroxy-(C1-C6)-alkyl-NH—;
• Z is N or CH;
• R1 is selected from the group consisting of (C1-C18)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C6-C14)-aryl, (C6-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl or (C5-C14)-heteroaryl-(C1-C8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by at least one member of the group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkoxy-(C1-C6)-alkyl-, (C1-C6)-alkoxycarbonyl-, (C1-C6)-alkylcarbonyl-, (C1-C6)-alkylaminocarbonyl-, (C1-C6)-alkoxy-(C1-C6)-alkoxy-, (C6-C14)-arylcarbonyl-, (C6-C14)-aryl-(C1-C8)-alkylcarbonyl-, (C1-C6)-alkanoylamino-, (C6-C14)-arylsulfonylamino-, (C1-C6)-alkylsulfonylamino-, (C1-C6)-alkylamino-, di-((C1-C6)-alkyl)-amino-, (C1-C6)-alkylsulfonyl-, (C1-C6)-alkylaminosulfonyl-, (C6-C14)-arylaminosulfonyl-, (C6-C14)-aryl-(C1-C8)-alkylaminosulfonyl-, (C6-C14)-arylsulfonyl-, (C6-C14)-aryl-(C1-C8)-alkylsulfonyl-, (C6-C14)-aryl and (C5-C14)-heteroaryl;
• R2 is selected from the group consisting of —C(O)R5, —C(S)R5, —S(O)pR5, —P(O)R5—R5′ a 4-membered to 8-membered saturated or unsaturated heterocycle which contains 1, 2, 3 or 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
• R3 is selected from the group consisting of (C1-C18)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C6-C14)-aryl, (C6-C14)-aryl-(C1-C8)-alkyl-, (C6-C14)-heteroaryl, (C6-C14)-heteroaryl-(C1-C8)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C1-C6)-alkoxy, (C1-C6)-alkoxy-(C1-C6)-alkyl-, (C1-C6)-alkoxycarbonyl-, (C1-C6)-alkyl-carbonyl-, (C5-C14)-arylcarbonyl-, (C1-C6)-alkylaminocarbonyl-, (C1-C6)-alkoxy-(C1-C6)-alkoxy-, (C6-C14)-aryl-(C1-C8)-alkylcarbonyl-, (C1-C6)-alkanoylamino-, (C1-C6)-alkylsulfonylamino-, (C6-C14)-arylsulfonylamino-, (C1-C6)-alkylamino-, di(C1-C6)-alkyl)amino-, (C1-C6)-alkylsulfonyl-, aminosulfonyl-, (C6-C14)-arylsulfonyl-, (C6-C14)-aryl-(C1-C8)-alkylsulfonyl-, (C6-C14)-aryl and (C5-C14)-heteroaryl, where alkyl R3s are independent of one another;
• R4 is selected from the group consisting of hydrogen, (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C6-C14)-aryl and (C6-C14)-aryl-(C1-C8)-alkyl-;
• R5 and R5′— are individually selected from the group consisting of hydroxy, (C1-C8)-alkoxy, (C6-C14)-aryl-(C1-C8)-alkoxy-, (C1-C8)-alkylcarbonyloxy-(C1-C4)-alkoxy-, (C6-C14)-aryl-(C1-C8)-alkylcarbonyloxy-(C1-C8)-alkoxy- and NR6R6′, where R5 and R5′ are independent of one another;
• R6 and R6 are individually selected from the group consisting of hydrogen, (C1-C18)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C6-C14)-aryl where in the aryl, one, two, three, four or five ring carbon atoms can be replaced by heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and (C6-C14)-aryl-(C1-C8)-alkyl- where in the aryl of the aryl-alkyl-, one, two, three, four or five ring carbon atoms can be replaced by heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, or R6 and R6′ together with the nitrogen atom to which they are bonded form a 4-membered to 8-membered ring system which in addition to the nitrogen atom to which R6 and R6′ are bonded can contain one, two or three ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and which can be unsaturated or saturated, where all R6 and R6′ are independent of one another;
• r is zero;
• s is zero, one, two, three or four;
• v is one, two or three;
• and
• p is one or two;
• in all their stercoisomeric forms and mixtures thereof in all ratios, and their non-toxic, physiologically tolerable salts.